{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:36:35Z","timestamp":1790984195080,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","award":["AS-CFII-111-215"],"award-info":[{"award-number":["AS-CFII-111-215"]}],"id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch","doi-asserted-by":"publisher","award":["114-HCH001"],"award-info":[{"award-number":["114-HCH001"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch","doi-asserted-by":"publisher","award":["HR-114-H01"],"award-info":[{"award-number":["HR-114-H01"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch","doi-asserted-by":"publisher","award":["114-HCH034"],"award-info":[{"award-number":["114-HCH034"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG1F0161"],"award-info":[{"award-number":["CMRPG1F0161"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CFRPG1M0011"],"award-info":[{"award-number":["CFRPG1M0011"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-002-244"],"award-info":[{"award-number":["111-2314-B-002-244"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2314-B-182A-012"],"award-info":[{"award-number":["109-2314-B-182A-012"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-182A116"],"award-info":[{"award-number":["MOST 111-2314-B-182A116"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002-073-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-002-073-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2314-B-182A-104"],"award-info":[{"award-number":["MOST 110-2314-B-182A-104"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaad.2025.09.030","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:59:55Z","timestamp":1758131995000},"page":"458-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study"],"prefix":"10.1016","volume":"94","author":[{"given":"Hsien-Yi","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Chia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Jen","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Che","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Man","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hsuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yuan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaw-Ning","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying- Ming","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline Chung-yee","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Lun","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.09.030_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.09.030_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.09.030_bib5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.5021\/ad.2017.29.6.822","article-title":"Association of hepatitis B virus infection and psoriasis","volume":"29","author":"Suh","year":"2017","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib7","first-page":"1294","article-title":"Hepatitis C infection in Egyptian psoriatic patients: prevalence and correlation with severity of disease","volume":"44","author":"Youssef","year":"2015","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.jaad.2025.09.030_bib8","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","article-title":"Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists","volume":"16","author":"Pauly","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan","volume":"39","author":"Cho","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s13555-022-00726-w","article-title":"Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.09.030_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/dth\/8942831","article-title":"A retrospective study to investigate safety of receiving Interleukin-17 monoclonal antibody for psoriasis patients with hepatitis B virus","volume":"2025","author":"Wu","year":"2025","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.09.030_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2022.09.023","article-title":"The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: a case series","volume":"30","author":"Ch'en","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2025.09.030_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2024.01.039","article-title":"Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: a multicenter prospective cohort study","volume":"90","author":"Huang","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/annrheumdis-2018-214400","article-title":"Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy","volume":"78","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaad.2019.12.001","article-title":"Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study","volume":"85","author":"Chiu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40257-024-00887-8","article-title":"Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: a 12-Year multicenter cohort study","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2025.09.030_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2015.07.023","article-title":"Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis","volume":"73","author":"Manalo","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaad.2025.09.030_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2025.09.030_bib24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1086\/605561","article-title":"Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria","volume":"49","author":"McGovern","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib25","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2025.09.030_bib26","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s40264-014-0185-4","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2025.09.030_bib27","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jaad.2025.09.030_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B (Methodological)"},{"key":"10.1016\/j.jaad.2025.09.030_bib29","first-page":"772","article-title":"Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis","volume":"7","author":"Jazwinski","year":"2011","journal-title":"Gastroenterol Hepatol (Ny)"},{"key":"10.1016\/j.jaad.2025.09.030_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.5152\/tjg.2018.18032","article-title":"Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity","volume":"29","author":"Solay","year":"2018","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jaad.2025.09.030_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-Targeted therapy: analysis of 257 cases","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2025.09.030_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaad.2025.09.030_bib34","doi-asserted-by":"crossref","first-page":"e1203","DOI":"10.1111\/jdv.19186","article-title":"Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: a multicentric retrospective cohort study of 49 patients","volume":"37","author":"Ciolfi","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.09.030_bib35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib36","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1756-185X.14217","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib","volume":"24","author":"Wang","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaad.2025.09.030_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jaad.2025.09.030_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.09.030_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40261-022-01163-5","article-title":"Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection","volume":"42","author":"Megna","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaad.2025.09.030_bib40","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2025.09.030_bib41","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2025.09.030_bib42","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:54:09Z","timestamp":1780908849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225028142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0190962225028142"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.030","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}